source
- Leo Pharma to acquire experimental rare-skin disease drug dersimelagon in up to $435 million dealLeo Pharma announced it will acquire the rights to dersimelagon, an experimental oral therapy currently under FDA review, in a transaction that could total up to $435 million in upfront and near‑te…
- Merck partners with Sarah Cannon to accelerate community oncology trialsMerck and Sarah Cannon Research Institute announced a collaboration to improve patient access to oncology trials at community sites across the United States. The partnership will use SCRI’s Accele…